Use of anti-TNFalpha antibodies and another drug
First Claim
Patent Images
1. A method for treating a disorder in a human subject which disease is treatable with a TNFα
- antibody or antigen binding fragment thereof, comprising administering a composition to the human subject in need thereof, on a biweekly dosing regimen such that the disorder is treated, said composition comprising an anti-TNFα
antibody or an antigen binding portion thereof and administering one or more other drug(s).
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention is directed to a method of treating disorders in which TFNα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) in combination with another drug which is useful for treating the disorder. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing are also encompassed by the invention.
-
Citations
22 Claims
-
1. A method for treating a disorder in a human subject which disease is treatable with a TNFα
- antibody or antigen binding fragment thereof, comprising administering a composition to the human subject in need thereof, on a biweekly dosing regimen such that the disorder is treated, said composition comprising an anti-TNFα
antibody or an antigen binding portion thereof and administering one or more other drug(s). - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
- antibody or antigen binding fragment thereof, comprising administering a composition to the human subject in need thereof, on a biweekly dosing regimen such that the disorder is treated, said composition comprising an anti-TNFα
- 12. A pharmaceutical composition comprising 40 mg of D2E7, one or more other drug(s) and a pharmaceutically acceptable carrier.
-
17. A kit comprising a formulation comprising:
-
a) a pharmaceutical composition comprising an anti-TNFα
antibody and a pharmaceutically acceptable carrier;
b) one or more pharmaceutical compositions, each composition comprising one or more other drug(s) and a pharmaceutically acceptable carrier; and
c) instructions for biweekly dosing of the pharmaceutical composition for the treatment of a disorder in which an anti-TNFα
antibody or a binding portion thereof is effective in treating. - View Dependent Claims (18, 19, 20, 21, 22)
-
Specification